Lutetium-177: all 36 studies that test it

Page 1 of 1. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.

• Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung CancerRecruitingNCT07689643Early Phase 1
• A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid TumorsRecruitingNCT07661641Phase 1
• Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsRecruitingNCT07660055Phase 1
• [177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade GliomaRecruitingNCT07655869Early Phase 1
• Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent GlioblastomaRecruitingNCT07648823Early Phase 1
• First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic CancerRecruitingNCT07608848Early Phase 1
• A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT07274852Phase 1
• A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsRecruitingNCT07232407Phase 1
• Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow FunctionRecruitingNCT07169825Phase 4
• A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate CancerRecruitingNCT07096128Phase 1
• A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast CancerRecruitingNCT07081555Phase 1
• Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentRecruitingNCT06955169Phase 2
• Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate CancerRecruitingNCT06866938Phase 2
• [177Lu]Lu-AKIR001 First-in-human StudyRecruitingNCT06639191Early Phase 1
• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersRecruitingNCT06562192Phase 1
• A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid TumorsNot yet recruitingNCT06553846Phase 1
• Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC）Not yet recruitingNCT06546527Early Phase 1
• A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine NeoplasmsRecruitingNCT06398444Phase 2/3
• A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced CancerRecruitingNCT06184035Phase 1/2
• Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate CancerRecruitingNCT06081686Phase 1/2
• Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine TumorsNot yet recruitingNCT05894486Phase 2
• An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.RecruitingNCT05884255Phase 3
• [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and ApplicationRecruitingNCT05458544Phase 1/2
• Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLsActive, not recruitingNCT04711135Phase 2Results posted
• Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06CompletedNCT07299253Early Phase 1
• Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPCWithdrawnNCT06881823Phase 1/2
• Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane AntigenCompletedNCT06641219Phase 1
• A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate CancerTerminatedNCT06516510Early Phase 1
• NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Active, not recruitingNCT06379217Phase 1
• Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.Active, not recruitingNCT06356922Phase 1/2
• A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.Active, not recruitingNCT06247995Phase 1/2
• [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerActive, not recruitingNCT05870579Phase 1
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPCCompletedNCT05670106Phase 2
• A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate CancerActive, not recruitingNCT05658003Phase 2
• A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETsActive, not recruitingNCT05459844Phase 3
• Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine TumorsActive, not recruitingNCT05249114Phase 1

← Lutetium-177 overview